A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

J Glaspy, J S Jadeja, G Justice, J Kessler, D Richards, L Schwartzberg, J Rigas, D Kuter, D Harmon, D Prow, G Demetri, D Gordon, J Arseneau, A Saven, H Hynes, R Boccia, J O'Byrne, A B Colowick, J Glaspy, J S Jadeja, G Justice, J Kessler, D Richards, L Schwartzberg, J Rigas, D Kuter, D Harmon, D Prow, G Demetri, D Gordon, J Arseneau, A Saven, H Hynes, R Boccia, J O'Byrne, A B Colowick

Abstract

Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life. rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25 mcg kg(-1)wk(-1)) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose-response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg(-1)wk(-1)cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl(-1)respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing.

Copyright 2001 Cancer Research Campaign.

References

    1. J Am Soc Nephrol. 1999 Nov;10(11):2392-5
    1. Med Res Rev. 1999 May;19(3):223-48
    1. Semin Hematol. 2000 Oct;37(4 Suppl 6):14-7
    1. Br J Cancer. 2001 Apr;84 Suppl 1:11-6
    1. Am J Clin Pathol. 1987 Sep;88(3):374-8
    1. N Engl J Med. 1990 Jun 14;322(24):1689-92
    1. Transfusion. 1990 Oct;30(8):673-4
    1. Semin Oncol. 1992 Jun;19(3 Suppl 8):29-35
    1. J Clin Oncol. 1994 May;12(5):1058-62
    1. Stem Cells. 1995 Jan;13(1):32-7
    1. J Clin Oncol. 1997 Mar;15(3):1218-34
    1. Ann Oncol. 1998 Mar;9(3):239-41
    1. Semin Oncol. 1998 Jun;25(3 Suppl 7):43-6
    1. J Interferon Cytokine Res. 1998 Aug;18(8):555-9
    1. J Clin Oncol. 1998 Oct;16(10):3412-25
    1. Blood. 2000 Aug 1;96(3):823-33

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren